Association between obesity-related adipokines and colorectal cancer: A case-control study and meta-analysis

Table 1 Serum adipokine levels in patients with colorectal cancer and healthy controls n (%)

	Total	Case	Control	P value
Age1	66.5 ± 10.0	66.1 ± 10.0	66.9 ± 10.0	0.67
≤ 60	39 (19.5)	20 (20.0)	19 (19.0)
61-70	87 (43.5)	46 (46.0)	41 (41.0)
≥ 71	74 (37.0)	34 (34.0)	40 (40.0)
Sex				1.00
Male	120 (60.0)	60 (60.0)	60 (60.0)
Female	80 (40.0)	40 (40.0)	40 (40.0)
Serum levels
Adiponectin (μg/mL)1	6.0 ± 4.9	5.7 ± 4.4	6.2 ± 5.3	0.47
Leptin (ng/mL)1	7.8 ± 8.9	6.8 ± 9.3	8.8 ± 8.5	0.12
Resistin (ng/mL)1	3.9 ± 2.3	4.9 ± 2.3	2.8 ± 1.7	< 0.0001
IL-6 (pg/mL)1	21.0 ± 103.6	11.3 ± 11.8	30.8 ± 145.8	0.19
TNFα (pg/mL)	6.0 ± 13.2	6.4 ± 12.5	5.7 ± 13.9	0.68

¹Value is mean ± SD. P value for the comparison of cases and controls by t test or χ² test, as appropriate. TNF: Tumor necrosis factor; IL: Interleukin.

Table 2 Association between each obesity-related adipokine and colorectal cancer risk

	Case (n = 100)	Control (n = 100)	OR	OR1
	Adiponectin (μg/mL)
1st tertile	31	35	Ref.	Ref.
2nd tertile	39	28	1.57 (0.79-3.12)	1.76 (0.79-3.91)
3rd tertile	30	37	0.92 (0.46-1.81)	0.80 (0.34-1.87)
P-trend			0.80	0.65
	Leptin (ng/mL)
1st tertile	45	21	Ref.	Ref.
2nd tertile	26	41	0.30 (0.15-0.60)	0.37 (0.17-0.83)
3rd tertile	29	38	0.36 (0.18-0.72)	0.31 (0.14-0.73)
P-trend			0.05	0.01
	Resistin (ng/mL)
Low	30	70	Ref.	Ref.
High	70	30	5.44 (2.97-9.97)	6.08 (3.23-11.44)
P-trend			< 0.0001	< 0.0001
	IL-6 (pg/mL)
1st tertile	43	25	Ref.	Ref.
2nd tertile	26	42	0.36 (0.18-0.72)	0.46 (0.21-1.01)
3rd tertile	31	33	0.55 (0.27-1.10)	0.55 (0.24-1.26)
P-trend			0.82	0.14
	TNFα (pg/mL)
1st tertile	14	54	Ref.	Ref.
2nd tertile	34	32	4.10 (1.92-8.77)	5.08 (1.84-13.10)
3rd tertile	52	14	14.33 (6.23-32.95)	41.16 (12.62-134.23)
P-trend			< 0.01	< 0.01

OR: Age, sex matched odds ratio; OR1: Odds ratio after adjusting each obesity-related adipokines. IL: Interleukin; TNF: Tumor necrosis factor.